Resolian Appoints Rob Stachlewitz as New CEO

• Resolian has appointed Rob Stachlewitz as Chief Executive Officer, effective immediately.

• Former CEO Pat Bennett will transition to Chief Business Officer and President of Scientific Affairs.

Resolian, a global bioanalytical contract research organization (CRO), has announced significant leadership changes to support its expansion and operational capabilities. Rob Stachlewitz has been appointed as the new Chief Executive Officer (CEO), effective immediately. He succeeds Pat Bennett, who will take on the role of Chief Business Officer and President of Scientific Affairs.

Rob Stachlewitz comes to Resolian with extensive experience in pharmaceutical research and development. He previously served as Corporate Vice President and General Manager at Charles River, managing their largest site. Stachlewitz brings over 15 years of relevant experience, having held key positions at companies including Boehringer Ingelheim, Abbott Laboratories, and Procter & Gamble. In his new role, he will lead Resolian through its next phase of strategic growth.

Meanwhile, Pat Bennett, the outgoing CEO, will focus on expanding Resolian’s service capabilities and strengthening customer relationships in his new position. With more than 30 years of experience in bioanalytical sciences and business development, Bennett will oversee essential functions aimed at fostering client collaboration and operational synergies within the company.